151 related articles for article (PubMed ID: 17317345)
21. Combined oral and topical mesalazine treatment for extensive ulcerative colitis.
Moss AC; Cheifetz AS; Peppercorn MA
Nat Clin Pract Gastroenterol Hepatol; 2006 May; 3(5):290-3. PubMed ID: 16673009
[TBL] [Abstract][Full Text] [Related]
22. Topical corticosteroids in inflammatory bowel disease.
Mulder CJ; Rondas AA; Wiltink EH; Tytgat GN
Neth J Med; 1989 Jun; 35 Suppl 1():S27-34. PubMed ID: 2702309
[No Abstract] [Full Text] [Related]
23. [TNF-alpha antibody treatment and remission induction in ulcerative colitis: a review of a Cochrane review].
Bjerrum JT; Munck LC; Krogh-Madsen M; Nielsen OH
Ugeskr Laeger; 2007 Feb; 169(9):792-5. PubMed ID: 17355842
[No Abstract] [Full Text] [Related]
24. Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis.
Lichtenstein GR; Rubin DT; Sabesin SM; Velayos FS; Vitat P
Rev Gastroenterol Disord; 2008; 8(1):21-30; quiz 31-2. PubMed ID: 18477967
[TBL] [Abstract][Full Text] [Related]
25. [Chronic inflammatory bowel diseases. Do antihistaminics reduce the need for steroids?].
MMW Fortschr Med; 2000 Jun; 142(22):59. PubMed ID: 10870388
[No Abstract] [Full Text] [Related]
26. Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
Hanauer SB
Aliment Pharmacol Ther; 2008 Mar; 27 Suppl 1():15-21. PubMed ID: 18307645
[TBL] [Abstract][Full Text] [Related]
27. [Activity indices--objective criteria of the estimation of severity level of ulcerous colitis].
Bakulin IG; Stanke DA; Belousova EA; Golovenko OV; Mikhailova TL
Eksp Klin Gastroenterol; 2008; (6):14-6. PubMed ID: 19334421
[No Abstract] [Full Text] [Related]
28. Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis.
Monteleone G; Caprioli F
Curr Opin Investig Drugs; 2007 May; 8(5):423-8. PubMed ID: 17520872
[TBL] [Abstract][Full Text] [Related]
29. Once-daily mesalamine (Lialda) for ulcerative colitis.
Med Lett Drugs Ther; 2007 Mar; 49(1257):25-6. PubMed ID: 17375030
[No Abstract] [Full Text] [Related]
30. [News from the Cochrane Library: Maintenance of remission in ulcerative colitis].
Timmer A
Z Gastroenterol; 2007 May; 45(5):395-6. PubMed ID: 17503319
[No Abstract] [Full Text] [Related]
31. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
Safdi AV; Cohen RD
Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
[TBL] [Abstract][Full Text] [Related]
32. Ulcerative colitis treatment for children and teens.
FDA Consum; 2007; 41(2):5. PubMed ID: 17582854
[No Abstract] [Full Text] [Related]
33. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of catarrhal and catarrho-erosive colitis with Repredsol (a new combination drug for topical application)].
Sirakov P
Vutr Boles; 1973; 12(4):92-7. PubMed ID: 4770082
[No Abstract] [Full Text] [Related]
35. Nephrotic syndrome and Moya-moya syndrome in a patient with ulcerative colitis.
Xinmei Z; Yan C
Inflamm Bowel Dis; 2012 Apr; 18(4):E798-800. PubMed ID: 21987371
[No Abstract] [Full Text] [Related]
36. Is keeping the colon the ultimate marker of success in ulcerative colitis?
Nguyen GC; Prather CM
Gastroenterology; 2009 Oct; 137(4):1204-6. PubMed ID: 19717125
[No Abstract] [Full Text] [Related]
37. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
[TBL] [Abstract][Full Text] [Related]
38. Ulcerative colitis associated with leukocytoclastic vasculitis of the skin.
Tripodi Cutrì F; Salerno R; Lo Schiavo A; Gravina AG; Romano M; Ruocco E
Dig Liver Dis; 2009 Jul; 41(7):e42-4. PubMed ID: 18799375
[TBL] [Abstract][Full Text] [Related]
39. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
40. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
Osterman MT; Lichtenstein GR
Methods Find Exp Clin Pharmacol; 2009; 31(1):41-6. PubMed ID: 19357797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
